CaniPRBC - Canine Packed Red Blood Cells

Country: Australia

Language: English

Source: APVMA (Australian Pesticides and Veterinary Medicines Authority)

Active ingredient:

CANINE ERYTHROCYTES; SAGM - RED CELL NUTRIENT SOLUTION; SODIUM CITRATE; CANINE PLASMA

Available from:

PLASVACC PTY LTD

INN (International Name):

canine erythrocytes

Pharmaceutical form:

PARENTERAL LIQUID/SOLUTION/SUSPENSION

Composition:

CANINE ERYTHROCYTES BLOOD PRODUCT Active 60.0 ml/100ml; SAGM - RED CELL NUTRIENT SOLUTION BLOOD PRODUCT Other 100.0 ml; SODIUM CITRATE MINERAL-SODIUM-SALT Other 5.0 ml; CANINE PLASMA BIOLOGICAL-GENERAL Other 10.0 ml

Units in package:

350ml

Class:

VM - Veterinary Medicine

Therapeutic area:

MISCELLANEOUS VETERINARY

Product summary:

Poison schedule: 0; Withholding period: WHP: 0 days; Host/pest details: DOG: [ANAEMIA]; Poison schedule: 0; Withholding period: ; Host/pest details: DOG: [ANAEMIA]; As an aid in the treatment of acute anaemia in dogs.

Authorization status:

Registered

Authorization date:

2023-07-01

Patient Information leaflet

PLASVACC PTY LTD
CaniPRBC - Canine Packed Red Blood Cells
81359/102893
Company Name:
Product Name:
APVMA Approval No:
Label Name:
CaniPRBC - Canine Packed Red Blood Cells
Signal Headings:
FOR ANIMAL TREATMENT ONLY
Constituent
Statements:
Active Constituent: Canine Erythrocytes (RBC) 40-60mL/100mL
Also contains: Sodium Citrate as an anticoagulant ~5.0mL, SAGM® as a
red cell nutrient
solution 100mL and <10mL canine plasma.
Claims:
Indication: As an aid in the treatment of acute anaemia in dogs.
Net Contents:
CONTENTS: ≥ 350mL total volume
Directions for Use:
Restraints:
Contraindications:
Precautions:
PRECAUTIONS:
Administration of excessive volumes of this product, or at excessive
flow rates may result in
volume overload, citrate toxicity or anticoagulation in the recipient.
Do not administer if the bag is damaged or leaking, or the contents
appear discoloured,
cloudy or clumped.
Isotonic saline may be given through the same IV line but not those
fluids containing
calcium ions (e.g. Hartmann`s solution) or any other medications.
Side Effects:
SIDE EFFECTS: The recipient should be observed throughout and after
the transfusion for
hypersensitivity reactions such as urticaria, cutaneous hyperaemia or
oedema, especially in
facial areas and the ear pinnae.
Tachycardia or hyperthermia may also occur. If these signs occur, stop
the transfusion
immediately and investigate the cause. Treatment may be instigated
with IV fluids,
antihistamines, corticosteroids and/or adrenaline as appropriate. If
the signs resolve, the
transfusion may be restarted after 10-15 minutes. Pre-treatment with
antihistamines may
reduce the severity of these signs. RLP APPROVED
Dosage and
Administration:
DOSAGE AND ADMINISTRATION: All donors are DEA1.1 negative. Major
cross-matching
is however recommended pre-transfusion to ensure compatibility,
especially if the recipient
has a previous transfusion history.
The bag may be warmed to a maximum of 37ºC in a water bath and dried
thoroughly
thereafter, especially around the sterile transfusion ports

Safety Data Sheet

CANIPRBC
®
CANIPRBC
®
ACTIVE CONSTITUENT: Canine Erythrocytes (RBC) 40-60mL/100mL
ALSO CONTAINS: Sodium Citrate as an anticoagulant ~5.0mL, SAGM® as a
red cell
nutrient solution 100mL and <10mL canine plasma.
INDICATION: As an aid in the treatment of acute anaemia in dogs
CONTENTS: ≥ 350mL total volume
PRECAUTIONS: Administration of excessive volumes of this product, or
at
excessive flow rates may result in volume overload, citrate toxicity
or anticoagula-
tion in the recipient. Isotonic saline may be given through the same
IV line but not
those fluids containing calcium ions (e.g. Hartmann`s solution) or any
other
medications. The donors are not routinely screened for blood-borne
infectious
diseases. The blood is not treated in any way to inactivate pathogens.
No sterility
study has been performed on this product.
SIDE EFFECTS: The recipient should be observed throughout and after
the
transfusion for hypersensitivity reactions such as urticaria,
cutaneous hyperaemia or
oedema, especially in facial areas and the ear pinnae. Tachycardia or
hyperthermia
may also occur. If these signs occur, stop the transfusion immediately
and investigate
the cause. Treatment may be instigated with IV fluids, antihistamines,
corticosteroids
and/or adrenaline as appropriate. If the signs resolve, the
transfusion may be
restarted after 10-15 minutes. Pre-treatment with antihistamines15-20
mins prior to
the transfusion may reduce the severity of these signs.
DOSAGE AND ADMINISTRATION: All donors are DEA1.1 negative. Major
cross-matching is however recommended pre-transfusion to ensure
compatibility,
especially if the recipient has a previous transfusion history. The
bag may be warmed
to a maximum of 37ºC in a water bath and dried thoroughly thereafter,
especially
around the sterile transfusion ports, which should not be opened until
the giving set
is ready to be spiked into it.
Do not administer if the bag is damaged or leaking, or the contents
appear
discoloured, cloudy or clumped.
Administer by slow intravenous transfusion at